Pure Global AI
NCT06373146Not yet recruiting

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly and CompanyPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
Tirzepatide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Gardena,Irvine,Los Angeles,North Hollywood,Panorama City,Santa Ana,Walnut Creek,Meridian,Marrero,Metairie,Norfolk,Fargo,Corpus Christi,Dallas,Bellevue,Mexicali,Mexico City,Monterrey,Merida,Chihuahua, Mexico,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Apr 01, 2026
Enrollment
360 participants
Primary outcome

Mean Percent Change from Baseline in Body Weight

Summary

The main purpose of this study is to determine if combining tirzepatide with the mibavademab
 will result in more weight loss in adult participants than tirzepatide alone. The study will
 last about 72 weeks and may include up to 19 visits.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06373146
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06373146 through Pure Global AI's free database. This Phase 2 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 360 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.